Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time

被引:1
|
作者
Phadnis, Milind A. [1 ]
Mayo, Matthew S. [1 ]
机构
[1] Univ Kansas, Dept Biostat & Data Sci, Med Ctr, 3901 Rainbow Blvd, Kansas City, KS 66160 USA
关键词
Generalized gamma; noninferiority; non-proportional hazards; proportional time; relative time; sample size; NON-INFERIORITY TRIALS; 2-SAMPLE INFERENCE; DESIGN; SURVIVAL; EQUIVALENCE; ISSUES; RATIO;
D O I
10.1080/02664763.2020.1753026
中图分类号
O21 [概率论与数理统计]; C8 [统计学];
学科分类号
020208 ; 070103 ; 0714 ;
摘要
Noninferiority trials intend to show that a new treatment is 'not worse' than a standard-of-care active control and can be used as an alternative when it is likely to cause fewer side effects compared to the active control. In the case of time-to-event endpoints, existing methods of sample size calculation are done either assuming proportional hazards between the two study arms, or assuming exponentially distributed lifetimes. In scenarios where these assumptions are not true, there are few reliable methods for calculating the sample sizes for a time-to-event noninferiority trial. Additionally, the choice of the non-inferiority margin is obtained either from a meta-analysis of prior studies, or strongly justifiable 'expert opinion', or from a 'well conducted' definitive large-sample study. Thus, when historical data do not support the traditional assumptions, it would not be appropriate to use these methods to design a noninferiority trial. For such scenarios, an alternate method of sample size calculation based on the assumption of Proportional Time is proposed. This method utilizes the generalized gamma ratio distribution to perform the sample size calculations. A practical example is discussed, followed by insights on choice of the non-inferiority margin, and the indirect testing of superiority of treatment compared to placebo.
引用
收藏
页码:1009 / 1032
页数:24
相关论文
共 50 条
  • [21] Sample size considerations for single-arm clinical trials with time-to-event endpoint using the gamma distribution
    Dai, Junqiang
    He, Jianghua
    Phadnis, Milind A.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 41
  • [22] Minimum sample size calculations for external validation of a clinical prediction model with a time-to-event outcome
    Riley, Richard D.
    Collins, Gary S.
    Ensor, Joie
    Archer, Lucinda
    Booth, Sarah
    Mozumder, Sarwar, I
    Rutherford, Mark J.
    van Smeden, Maarten
    Lambert, Paul C.
    Snell, Kym I. E.
    [J]. STATISTICS IN MEDICINE, 2022, 41 (07) : 1280 - 1295
  • [23] Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints
    Jordi Cortés Martínez
    Ronald B. Geskus
    KyungMann Kim
    Guadalupe Gómez Melis
    [J]. BMC Medical Research Methodology, 21
  • [24] Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints
    Martinez, Jordi Cortes
    Geskus, Ronald B.
    Kim, Kyung Mann
    Melis, Guadalupe Gomez
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [25] Sample size determination for time-to-event endpoints in randomized selection trials with generalized exponential distribution
    Akbar, Muhammad Hamza
    Ali, Sajid
    Shah, Ismail
    Alqifari, Hana N.
    [J]. HELIYON, 2024, 10 (05)
  • [26] Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size
    Xu, Rengyi
    Mehrotra, Devan V.
    Shaw, Pamela A.
    [J]. PHARMACEUTICAL STATISTICS, 2019, 18 (03) : 366 - 376
  • [27] Sample size calculation for randomized selection trials with a time-to-event endpoint and a margin of practical equivalence
    Dehbi, Hakim-Moulay
    Embleton-Thirsk, Andrew
    McCaw, Zachary Ryan
    [J]. STATISTICS IN MEDICINE, 2022, 41 (20) : 4022 - 4033
  • [28] Sample size adjustment designs with time-to-event outcomes: A caution
    Freidlin, Boris
    Korn, Edward L.
    [J]. CLINICAL TRIALS, 2017, 14 (06) : 597 - 604
  • [29] Sample size calculation for two-arm trials with time-to-event endpoint for nonproportional hazards using the concept of Relative Time when inference is built on comparing Weibull distributions
    Phadnis, Milind A.
    Mayo, Matthew S.
    [J]. BIOMETRICAL JOURNAL, 2021, 63 (07) : 1406 - 1433
  • [30] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    [J]. CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396